Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 12/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041959 | 0.74 | NTRK1 (0.37) | TLR9TLR8TLR7NTRK1 | |
| SCHEMBL14983679 | 0.69 | ROCK2 (0.35) | — | |
| SCHEMBL16091256 | 0.66 | NTRK1 (0.36) | TLR9TLR8TLR7NTRK1 | |
| SCHEMBL27975444 | 0.66 | LRRK2 (0.42) | TLR9TLR8TLR7NTRK1CYP1A2 | |
| SCHEMBL13616224 | 0.66 | BRD4 (0.42) | TLR9TLR8TLR7NTRK1 | |
| SCHEMBL19684530 | 0.66 | NTRK1 (0.40) | NTRK1CYP1A2USP2CYP3A4 | |
| SCHEMBL30968079 | 0.66 | NTRK1 (0.36) | TLR9TLR8TLR7NTRK1 | |
| SCHEMBL18629344 | 0.65 | PDK1 (0.34) | MEN1KMT2A | |
| SCHEMBL11922157 | 0.64 | NTRK1 (0.37) | NTRK1 | |
| SCHEMBL28811015 | 0.63 | NTRK1 (0.54) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932346-B2 | Pyrrolopyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-03 | — | — | US | disclosed |
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253600-A1 | PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | IMPDH1, IMPDH2, TYMP | TLR9 1540/4885TLR8 2028/4885TLR7 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.